AbstractA reversed-phase high-performance liquid chromatography method was developed and validated for the simultaneous determination of pridinol, diclofenac and diclofenac-related compounds in tablet formulations. The proposed method is also suitable for content uniformity determination, for dissolution test and for stability studies. Separation was achieved on a base-deactivated silica C8 column, using 50 mM phosphate buffer (pH 2.5) and methanol (40:60 v/v) as mobile phase, at a flow rate of 1.0 mL/min and column temperature of 40°C. Ultraviolet detection was made at 225 nm. The method was validated for specificity, accuracy, precision (intraday and interday levels) and linearity for each analyte. For diclofenac impurity A, sensitivity was also studied. The method showed specificity and linearity (R2: 0.999 for the three analytes) over the assessed concentration range (diclofenac: 2.5–75.0 μg/mL, pridinol: 2.0–60.0 μg/mL and impurity A: 1.25–5.0 μg/mL) and demonstrated good precision as reflected by the low coefficient of variation in all cases. Recovery rates obtained were 99.81, 100.58 and 100.96% for diclofenac, pridinol and impurity A respectively, and for all three analytes, the variances of the concentrations tested were equivalent. The detection and quantitation limits for impurity A were 0.078 and 0.261 μg/mL, respectively.

01 Dec 2023·BMJ Supportive & Palliative Care

Pridinol for cancer-related myofascial pain

Article

Author: Coyle, Séamus

Myofascial pain is an important yet under recognised component of cancer pain. It has a prevalence of between 11.9 and 44.8% in cancer patients. Treatments for myofascial pain reduce the prevalence of myofascial trigger points therefore decreasing pain and improving range of motion. Pridinol is a nonbenzodiazepine antispasmodic licenced for the treatment of central and peripheral muscle spasms in adults. This paper describes two case histories where patients with myofascial pain were successfully treated with pridinol. These cases highlight the importance of treating myofascial pain and the potential of pridinol to treat cancer-related myofascial pain.

03 Jul 2022·Current Medical Research and Opinion

Efficacy and tolerability of the antispasmodic, pridinol, in patients with muscle-pain – results of primepain, a retrospective analysis of open-label real-world data provided by the German pain E-registry

Article

Author: Horlemann, Johannes ; Müller-Schwefe, Gerhard H. H. ; Überall, Michael A.

OBJECTIVETo evaluate efficacy and tolerability of the nonbenzodiazepine antispasmodic pridinol (PRI), as an add-on treatment in patients with muscle-related pain (MRP).METHODSExploratory retrospective analysis of depersonalized routine data provided by the German Pain e-Registry (GPeR) focusing on pain intensity, pain-related disabilities in daily life, wellbeing, and drug-related adverse events (DRAEs).Primary endpoint based on a global response composite of (a) a clinically relevant analgesic response (relative improvement ≥50% and/or absolute improvement ≥ the minimal clinical important difference) for pain intensity and disability in combination with (b) an improvement in wellbeing (all at end of treatment vs. baseline), and (c) lack of any DRAEs.RESULTSBetween 1 January 2018 and 31 December 2020, the GPeR collected information on 121,803 pain patients of whom 1133 (0.9%; 54.5% female, mean ± SD age: 53.9 ± 11.8 years) received add-on PRI for the treatment of (mostly acute) MRP originating predominantly in the (lower) back (43.2%), lower limb (26.4%), or should/neck (21.1%). Average daily dose was 7.8 ± 1.8 (median 9, range 1.5-13.5) mg, duration of treatment 12.0 ± 10.2 (median 7, range 3-63) days. In total, 666 patients (58.8%) reported a complete, 395 (34.9%) a partial, and 72 (6.4%) patients no response - either because of lack of efficacy (n = 2, 0.2%) or DRAEs (n = 70, 6.2%). In response to PRI, 41.7% of patients documented a reduction of at least one other pain medication and 30.8% even the complete cessation of any other pharmacological pain treatments.CONCLUSIONBased on this real-world data of the German Pain e-Registry, add-on treatment with PRI in patients with acute MRP under real-world conditions in daily life was well tolerated and associated with an improvement of pain intensity, pain-related disabilities, and overall wellbeing.

100 Deals associated with Pridinol Mesilate

External Link

KEGG	Wiki	ATC	Drug Bank
D02064	Pridinol Mesilate	M03BX03	DB13642

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Muscle Spasticity	JP	Tobishi Pharmaceutical Co. Ltd.	01 Jan 1968

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis